A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
PHASE3Not yet recruitingINTERVENTIONAL
Enrollment
442
Participants
Timeline
Start Date
January 31, 2026
Primary Completion Date
January 31, 2027
Study Completion Date
April 30, 2027
Conditions
Spasticity
Interventions
DRUG
Arbaclofen
Arbaclofen Extended Release Tablets
DRUG
Placebo
Placebo tablets
All Listed Sponsors
lead
RVL Pharmaceuticals, Inc.
INDUSTRY
NCT05179577 - A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter